BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

498 related articles for article (PubMed ID: 24603117)

  • 21. Absolute bioavailability and pharmacokinetics of treprostinil sodium administered by acute subcutaneous infusion.
    Wade M; Baker FJ; Roscigno R; DellaMaestra W; Hunt TL; Lai AA
    J Clin Pharmacol; 2004 Jan; 44(1):83-8. PubMed ID: 14681345
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
    Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
    Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Extended-release oral treprostinil in the management of pulmonary arterial hypertension: clinical evidence and experience.
    Coons JC; Miller T
    Ther Adv Respir Dis; 2018; 12():1753466618766490. PubMed ID: 29609511
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative pharmacokinetic, pharmacodynamic, safety, and tolerability profiles of 3 different formulations of epoprostenol sodium for injection in healthy men.
    Nicolas LB; Gutierrez MM; Dingemanse J
    Clin Ther; 2013 Apr; 35(4):440-9. PubMed ID: 23498778
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Steady-state pharmacokinetics of once-daily cyclobenzaprine extended release: a randomized, double-blind, 2-period crossover study in healthy volunteers.
    Darwish M; Hellriegel ET
    Clin Ther; 2011 Jun; 33(6):746-53. PubMed ID: 21704239
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
    Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
    Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetic evaluation of treprostinil (oral) for the treatment of pulmonary arterial hypertension.
    Hellawell JL; Bhattacharya S; Farber HW
    Expert Opin Drug Metab Toxicol; 2014 Oct; 10(10):1445-53. PubMed ID: 25204984
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dose proportionality of treprostinil sodium administered by continuous subcutaneous and intravenous infusion.
    McSwain CS; Benza R; Shapiro S; Hill N; Schilz R; Elliott CG; Zwicke DL; Oudiz RJ; Staszewski JP; Arneson CP; Wade M; Zaccardelli D; McLaughlin V
    J Clin Pharmacol; 2008 Jan; 48(1):19-25. PubMed ID: 18094217
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertension.
    Channick RN; Olschewski H; Seeger W; Staub T; Voswinckel R; Rubin LJ
    J Am Coll Cardiol; 2006 Oct; 48(7):1433-7. PubMed ID: 17010807
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety, tolerability and pharmacokinetics of doravirine, a novel HIV non-nucleoside reverse transcriptase inhibitor, after single and multiple doses in healthy subjects.
    Anderson MS; Gilmartin J; Cilissen C; De Lepeleire I; Van Bortel L; Dockendorf MF; Tetteh E; Ancona JK; Liu R; Guo Y; Wagner JA; Butterton JR
    Antivir Ther; 2015; 20(4):397-405. PubMed ID: 25470746
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treprostinil for the treatment of pulmonary arterial hypertension.
    Torres F; Rubin LJ
    Expert Rev Cardiovasc Ther; 2013 Jan; 11(1):13-25. PubMed ID: 23259441
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety, tolerability, pharmacokinetics, and pharmacodynamics of fimasartan following single and repeated oral administration in the fasted and fed states in healthy subjects.
    Chi YH; Lee H; Paik SH; Lee JH; Yoo BW; Kim JH; Tan HK; Kim SL
    Am J Cardiovasc Drugs; 2011 Oct; 11(5):335-46. PubMed ID: 21910510
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics of Oral Treprostinil in Children With Pulmonary Arterial Hypertension.
    Hopper RK; Ivy DD; Yung D; Mullen MP; Hanna BD; Kirkpatrick E; Hirsch R; Austin ED; Fineman J; Solum D; Deng CQ; Feinstein JA
    J Cardiovasc Pharmacol; 2020 Jul; 76(1):94-100. PubMed ID: 32398473
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetic comparison of a new glimepiride 1-mg + metformin 500-mg combination tablet formulation and a glimepiride 2-mg + metformin 500-mg combination tablet formulation: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy, fasting Korean male volunteers.
    Kim BH; Shin KH; Kim J; Lim KS; Kim KP; Kim JR; Cho JY; Shin SG; Jang IJ; Yu KS
    Clin Ther; 2009 Nov; 31(11):2755-64. PubMed ID: 20110017
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of age, gender, and diurnal variation on the steady-state pharmacokinetics of BMS-181101, an antidepressant, in healthy subjects.
    Srinivas NR; Shyu WC; Gleason C; Schuster A; Greene DS; Barbhaiya RH
    Clin Pharmacol Ther; 1997 Oct; 62(4):408-16. PubMed ID: 9357392
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rapid transition from inhaled iloprost to inhaled treprostinil in patients with pulmonary arterial hypertension.
    Bourge RC; Tapson VF; Safdar Z; Benza RL; Channick RN; Rosenzweig EB; Shapiro S; White RJ; McSwain CS; Gotzkowsky SK; Nelsen AC; Rubin LJ
    Cardiovasc Ther; 2013 Feb; 31(1):38-44. PubMed ID: 22970909
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhaled treprostinil for the treatment of pulmonary arterial hypertension.
    LeVarge BL; Channick RN
    Expert Rev Respir Med; 2012 Jun; 6(3):255-65. PubMed ID: 22788940
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of switching from epoprostenol to IV treprostinil on treatment satisfaction and quality of life in patients with pulmonary hypertension.
    Minai OA; Parambil J; Dweik RA; Davila GH; Peterson L; Rollins KD; Chen H
    Respir Med; 2013 Mar; 107(3):458-65. PubMed ID: 23266038
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics of a once-daily extended-release formulation of pramipexole in healthy male volunteers: three studies.
    Jenner P; Könen-Bergmann M; Schepers C; Haertter S
    Clin Ther; 2009 Nov; 31(11):2698-711. PubMed ID: 20110012
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Comprehensive Review of Treprostinil Pharmacokinetics via Four Routes of Administration.
    Kumar P; Thudium E; Laliberte K; Zaccardelli D; Nelsen A
    Clin Pharmacokinet; 2016 Dec; 55(12):1495-1505. PubMed ID: 27286723
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.